|Year : 2014 | Volume
| Issue : 6 | Page : 514-520
Primary central nervous system lymphoma: An Indian Perspective
KC Lakshmaiah1, Vishwanath Sathyanarayanan1, K Govind Babu1, D Lokanatha1, KN Lokesh1, MC Babu1, Clementina Rama Rao2, CS Premalatha2, TM Suresh1, Vineetha Unnikrishnan1, Linu Jacob Abraham1
1 Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
2 Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
|Date of Web Publication||11-Oct-2014|
Department of Medical Oncology, OPD 5, Kidwai Memorial Institute of Oncology, Dr. MH Marigowda Road, Bengaluru - 560 029, Karnataka
Source of Support: None, Conflict of Interest: None
Context: Primary central nervous system lymphoma (PCNSL) is an unusual entity comprising around 5% of extra nodal lymphomas with a dismal prognosis in spite of a multi-modality treatment protocol involving chemotherapy and radiotherapy. There is sporadic data from this part of the world and hence we took up this study to analyze the outcome with various modalities of treatment. Materials and Methods: We undertook this study between January 2007 and January 2013 on 33 consecutive patients diagnosed with PCNSL to analyze the clinical profile and treatment outcomes of PCNSL at a tertiary care oncology center in South India. Twelve patients received the DeAngelis protocol and the remaining 21 patients received either radiotherapy or a combination of radiotherapy and anthracycline based therapy or steroids. This study also compared the outcomes with protocols of DeAngelis et al. and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with/out radiotherapy. Results: A total of 33 patients with PCNSL were studied. Median age was 40 years (range 22-75 years). Male: Female ratio was 3.1:1. All 33 were histologically diffuse large B-cell lymphoma (DLBCL). HIV was positive in 1. The most common presenting symptom was focal neurological deficits in 19 (58%). Cerebrospinal fluid was positive in 2 (6%). The area of involvement was mainly cerebral hemispheres 20 (61%). The treatment protocols followed were DeAngelis in 12, cyclophosphamide, doxorubicin, vincristine and prednisolone with radiotherapy (CHOP + radiation therapy [RT]) in 12, RT alone in 6, CHOP in 2 and 1 received no therapy. On a median follow-up of 17 months, the median overall survival was 15 months (range 1-60 months) with DeAngelis protocol and 12 months (range 8-24 months) with CHOP + RT. Conclusions: DeAngelis protocol has improved the prognosis in patients with PCNSL compared with other protocols as shown in our study. Newer chemotherapy regimens or targeted therapies need to be evaluated to further improve the survival.
Keywords: DeAngelis protocol, cyclophosphamide, doxorubicin, vincristine, and prednisone, India, primary central nervous system lymphoma
|How to cite this article:|
Lakshmaiah K C, Sathyanarayanan V, Babu K G, Lokanatha D, Lokesh K N, Babu M C, Rao CR, Premalatha C S, Suresh T M, Unnikrishnan V, Abraham LJ. Primary central nervous system lymphoma: An Indian Perspective. Clin Cancer Investig J 2014;3:514-20
|How to cite this URL:|
Lakshmaiah K C, Sathyanarayanan V, Babu K G, Lokanatha D, Lokesh K N, Babu M C, Rao CR, Premalatha C S, Suresh T M, Unnikrishnan V, Abraham LJ. Primary central nervous system lymphoma: An Indian Perspective. Clin Cancer Investig J [serial online] 2014 [cited 2021 Jan 20];3:514-20. Available from: https://www.ccij-online.org/text.asp?2014/3/6/514/142642
| Introduction|| |
Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma involving only the (CNS-brain parenchyma, spinal cord, eyes, cranial nerves, and/or meninges.  It is an unusual entity comprising around 5% of extra nodal lymphomas with a dismal prognosis in spite of a multi-modality treatment protocol. Most of the PCNSL are histologically diffuse large B-cell lymphoma (DLBCL). The prognosis of patients with PCNSL is dismal and inferior compared with DLBCL occurring in other sites. PCNSL exhibits unique biologic features and only certain drugs penetrate the blood brain barrier and give a therapeutic benefit. Moreover, the patients with PCNSL generally have a poor Eastern Cooperative Oncology Group (ECOG) performance status at presentation and delivering the right chemotherapeutic drug with minimal toxicity and achieving the maximum benefit becomes a challenge. Long-term follow-up of these patients with special emphasis to radiation induced neurotoxicity is also an important aspect of the management.  Various chemotherapeutic regimens, including high-dose methotrexate (HD-MTX), high-dose cytarabine, procarbazine and vincristine have been tried. Anthracycline based regimens have also been tried and studies are on to assess the role of rituximab both systemically and intrathecally. Other newer drugs like temozolamide have also been tried in relapsed and progressive disease with limited success. We undertook this study at our center to analyze the profile and outcome in our patients with PCNSL treated with DeAngelis Protocol or radiotherapy alone or a combination of radiotherapy and anthracycline based therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]). The DeAngelis protocol  consists of 19 weeks of therapy, which involves chemotherapy and radiotherapy. It involves a combination of MTX, intrathecal MTX, vincristine, procarbazine, dexamethasone, high-dose cytarabine, and whole brain radiotherapy (WBRT). CHOP was given q3 weekly in this study.
| Materials and methods|| |
This was a retrospective study, undertaken at Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India between January 2007 and January 2013 on 33 consecutive patients diagnosed with PCNSL. Twelve patients received the DeAngelis protocol and the remaining 21 patients received either radiotherapy or a combination of radiotherapy and anthracycline based therapy.
The DeAngelis protocol  is summarized below:
- MTX intravenous (iv) 2.5 g/m 2 on weeks 1, 3, 5, 7 and 9
- Vincristine iv 1.4 mg/m 2 on weeks 1, 3, 5, 7, 9
- Procarbazine per oral 100 mg/m 2 /day for 7 days on weeks 1, 5, 9
- Intrathecal MTX 12 mg on weeks 2, 4, 6, 8, 10
- Leucovorin per oral 20 mg every 6 h for 12 doses on weeks 1, 3, 5, 7, and 9 following MTX
- Dexamethasone per oral tapering dose for 7 days (16, 12, 8, 6, 4, 2 mg on weeks 1-6)
- WBRT was planned for a total dose of 45 Gy in 1.80 Gy fractions (weeks 11-15)
- Cytarabine 3 g/m 2 /day for 2 days on weeks 16 and 19.
The CHOP regimen included: Cyclophosphamide 750 mg/m 2 iv d1, Vincristine 1.4 mg/m 2 iv d1, adriamycin 50 mg/m 2 iv d1, prednisolone PO 100 mg/day × 5 days. This regimen was given q3 weekly for 6 cycles.
All the patients underwent a detailed history and physical examination including a neurological assessment. Investigations directed to the diagnosis - contrast-enhanced computed tomography (CT) of the brain or magnetic resonance imaging, positron emission tomography (if affordable), cerebrospinal fluid (CSF) analysis for cytology, histopathological diagnosis (following stereotactic or open biopsy), CT of the thorax and abdomen and bone marrow biopsy were done. Investigations to assess the general status, including hemogram, comprehensive metabolic profile, chest X-ray, and two-dimensional-echocardiography were also done. Memorial-Sloan Kettering Cancer Center (MSKCC) prognostic score was calculated. Class 1 - patients < 50 years. Class 2 - patients ≥ 50 years; Karnofsky performance status (KPS) ≥70. Class 3 - patients ≥ 50 years; KPS <70. A diagnosis of PCNSL was made only if the primary site of involvement was brain, spinal cord, meninges or eyes. Involvement of other sites other than the above were included under secondary lymphoma with CNS involvement and hence excluded from the study. Median overall survival (OS) was calculated from the date of diagnosis to the date of death.
| Results|| |
Of the 33 patients who were studied, median age was 40 years (range 22-75 years). Male: Female ratio was 3.1:1. All were histologically DLBCL. Of 33 patients of PCNSL, one patient had HIV positivity. B symptoms are very uncommon in patients with PCNSL and 7 out of 33 patients (21.21%) had B symptoms in our study. The most common presenting symptoms were focal neurological deficits (hemi paresis, cranial nerve palsies, aphasia, cerebellar signs), followed by raised intracranial tension features, neuropsychiatric features, seizures and ocular symptoms. This has been summarized in [Table 1]. CSF cytology was positive in two patients (6%). The median serum lactate dehydrogenase (LDH) was 234 U/L and was elevated in nine patients (27%). The area of involvement was mainly cerebral hemispheres 20 (61%), periventricular regions 8 (24%), thalamus in 9 (27%), leptomeninges in 3 (9%), corpus callosum in 5 (15%) and cerebellum in 4 (12%). It has been summarized in [Table 2]. The risk stratification according to MSKCC risk score was Class 1 in 61%, class 2 in 12% and Class 3 in 27%. The diagnostic procedures employed were stereotactic biopsy in 49%, surgical decompression in 24%, excisional biopsy in 18% and open biopsy in 9%. The treatment protocols followed were DeAngelis in 12, CHOP + radiation therapy (RT) in 12, RT alone in 6, CHOP in 2 and 1 received no therapy. The median OS was 15 months (range 1-60 months) with DeAngelis protocol and 12 months (range 8-24 months) with CHOP + RT [Table 3].
|Table 1: Summarizing clinical presentation of the 33 patients in our study|
Click here to view
| Discussion|| |
Primary central nervous system lymphoma is an unusual entity comprising approximately 3-4% of all intracranial neoplasms and 5% of extra nodal lymphomas. It is a tumor confined to the CNS involving the brain parenchyma, leptomeninges, spinal cord and also the eyes. , Involvement of these sites in the context of systemic manifestations is secondary CNS lymphoma. It presents most commonly with focal neurological deficits and has a dismal prognosis in spite of various chemotherapeutic and radiation oncological interventions.
The only documented and established role as a risk factor is congenital or acquired immune deficiency. Though HIV was a major cause of PCNSL in the 1980s and 1990s, the trend has changed with the introduction of antiretroviral therapy (ART). With the advent of ART, the incidence in HIV positive individuals was reduced and on the contrary, the incidence in immune competent individuals is increasing manifold. 
This pattern is also seen in our series from a regional cancer center, where we analyzed 33 consecutive patients with PCNSL over the last 6 years, there was only one patient with HIV positivity. Histologically, more than 90% of PCNSLs are DLBCL with expression of B-cell markers - CD19, CD20, CD22, CD79a and BCL-6 and presence of immunoblasts and centroblasts with an affinity for blood vessels. Burkitt's and T-cell lymphomas account for the remaining 10% of the cases encountered. ,
Primary central nervous system lymphoma arises from late germinal center lymphoid cells and confined to the CNS. Gene expression studies have revealed germinal center type, activated B-cell type and large B-cell variants of DLBCL.  Though there are no B lymphocytes in the CNS, activated B lymphocytes from elsewhere in the body, which have acquired unique surface markers enter the CNS and multiply in an environment where there is no immunological surveillance. 
Various pathogenesis mechanisms have been suggested for the development of PCNSL including interaction of extracellular matrix proteins confined to the CNS and tumor cells, the NF-kB activation, inactivation of p14ARF and p16INK4a and the upregulation of IL-4 pathway with its major mediator, the activated form of STAT6. High STAT6 has also got prognostic significance with patients poorly responding to MTX based chemotherapy. Up regulation of osteopontin (SPP1) is also observed in PCNSL, which is involved in CNS tropism and B-cell migration.  Other mechanisms for the development of PCNSL include mutations in the PRDM1 gene, missense polymorphism D919G in methionine synthase, CpG island promoter hypermethylation, vascular endothelial growth factor (VEGF) up regulation and altered homocysteine and folate metabolism. ,, The median age of diagnosis for PCNSL is around 60 years in immunocompetent individuals with a male preponderance. In our study, the median age was 40 years (range 22-75 years) with a male preponderance (1.3:1). In immunocompromised patients, PCNSL incidence is two decades earlier. 
However, in our study, there was one patient with HIV positivity who received DeAngelis protocol. B symptoms are very uncommon in patients with PCNSL and a similar observation was made in our study with only 21.21% having B symptoms.  Patients present with focal neurological deficits, organic brain syndromes, and personality changes.  Patients can also present with increased intracranial tension features presenting with headaches, nausea and vomiting. In our study, focal neurological deficits were seen in 19 (58%) - the most common symptom followed by raised intracranial features in 10 (30%). Seven presented with memory disturbances and five presented with seizures. Seizures are not quite common as the tumor mainly involve the sub cortical white matter rather than the epileptogenic grey matter.  Five of our patients who had seizures had involvement of frontal cortex. Ocular symptoms are seen in around 10% of patients. Three of our patients (9%) had visual blurring.  Making a diagnosis of PCNSL should be made with caution and exclusion of systemic lymphoma with CNS involvement is a prerequisite. Evaluation should include examination of enlarged and testicular examination as primary testicular lymphoma has a predilection for the CNS. The International PCNSL collaborative group guidelines were used to diagnose PCNSL and also excludes systemic lymphoma.  The guidelines include a detailed history and physical examination, ophthalmological evaluation, HIV serology, LDH, CSF cytology, flow cytometry and immunoglobulin heavy chain polymerase chain reaction. Imaging includes CT brain, thorax, abdomen and pelvis, MRI brain and testicular ultrasonography in elderly men. Concurrent meningeal involvement is detected by CSF cytology examination in 16% of patients and in our study, CSF cytology was positive in two patients (6%).  We did all the above investigations except CSF flow cytometry and immunoglobulin heavy chain assessment in CSF due to financial constraints.  MRI brain, contrast-enhanced CT brain and PET scan are used to diagnose PCNSL. They present as solitary or multifocal lesions which are isointense or hypointense on T2-weighted MRI, with perilesional edema and homogeneous contrast-enhancement.  Where MRI is not possible, contrast-enhanced CT scan of the brain is done. The lesions are usually found in hemispheres, basal ganglia, corpus callosum, and periventricular regions. Various oncological and non oncological conditions-gliomas, metastases, tuberculosis, toxoplasmosis, sarcoidosis, and progressive multifocal leukoencephalopathy are to be considered in the list of differential diagnosis.  In our study, multifocal involvement was more common - seen in 70% of the patients, which is in contrary to other studies where solitary lesions are common.
Most PCNSL involve deeper structures of the brain in contrary to inflammatory conditions. Nevertheless, it is not possible to diagnose this entity radiologically with 100% accuracy. 18F-fluorodeoxyglucose PET-CT scanning can be done to differentiate from PCNSL from systemic lymphoma involving CNS. Use of PET-CT scanning has also been used in other studies to exclude an occult systemic lymphoma.  In our study, we used 18F-fluorodeoxyglucose PET-CT scanning for one of our patient (61 year/female) who had progressive disease following DeAngelis protocol. International Extranodal Lymphoma Study Group (IELSG) scoring system and the MSKCC prognostic score based on age, performance status (PS), and extent of disease are used to assess the prognosis of patients with PCNSL. The IELSG prognostic score includes age more than 60 years, ECOG score more than 1 (KPS < 70%), elevated serum LDH level, high CSF protein concentration, and involvement of the deep regions of the brain (periventricular regions, basal ganglia, brainstem, and/or cerebellum). , In our study, we used the MSKCC score and a higher score was associated with a poor survival. Treatment involves a multi-modality approach of chemotherapy and RT. Surgery is not shown to be advantageous and studies have not shown a difference in OS. Craniotomy for decompression of the mass (no change in outcome)/stereotactic/open biopsy is required for a histopathological diagnosis.  The treatment of this entity has evolved over the years with radiotherapy in the form of WBRT being the most important treatment until the early 2000s. WBRT is associated with a higher complete response rate (CRR), but also high recurrence rate. Hence, it has been more or less replaced by combining chemotherapy to the WBRT. These chemotherapeutic agents should have the capability to cross the blood brain barrier. HD-MTX is widely recognized as the single most effective chemotherapeutic agent for PCNSL. In a large study by DeAngelis et al. in 2002,  involving 102 newly diagnosed immunocompetent patients with PCNSL, patients first received five cycles of HD-MTX, vincristine, procarbazine and intraventricular MTX (12 mg). WBRT was administered to a total dose of 45 Gy and all patients received high-dose cytarabine after WBRT. Fifty-eight percent of patients with measurable disease had a CR to preirradiation chemotherapy and 36% had a partial response, with a 94% response rate. Median progression-free survival (PFS) was 24.0 months and OS was 36.9 months. Yi et al. in 2006 reported his data of 18 patients with DeAngelis protocol with a median OS of 26 months.  In an Indian study by Agarwal et al., 22 patients were studied with DeAngelis protocol. They reported a median OS of 10 months.  Shah et al. demonstrated a CRR of 78% with DeAngelis protocol and an estimated 2 years PFS and OS was 57% and 67% after a median follow-up of 37 months.  Rubenstein et al. studied 44 patients with immunochemotherapeutic regimen in a multicenter cooperative group trial without WBRT. In this trial, patients were treated with induction chemotherapy consisting of HD MTX at 8 g/m 2 (day 1, q 2 weekly for the first 7 doses with leucovorin rescue 100 mg/m 2 q 6 hourly until MTX level < 0.05 nM, rituximab at 375 mg/m 2 (day 3 once per week × 6 doses), and temozolomide at 150 mg/m 2 (days 7-11 of first 5 months)- MTR induction. MTR induction was followed by consolidation chemotherapy that included intravenous etoposide 5 mg/kg as a continuous infusion over 96 h (total 40 mg/kg) and cytarabine at 2 g/m 2 every 12 h for 8 doses. The CRR on induction chemotherapy was 66%. With a median follow up of 4.9 years, the 2 years PFS was 57% and the median OS was not reached. 
In our study, we used DeAngelis protocol or RT + CHOP or only RT. On a median follow-up of 17 months, the OS was 15 months (range 1-60 months) with DeAngelis protocol and 12 months with CHOP + RT. The comparison of other studies where DeAngelis protocol was used with our study has been summarized in [Table 4]. The clinical characteristics of our patients where DeAngelis protocol was used is also mentioned in [Table 5]. Anthracycline based chemotherapy - CHOP has been used in patients with PCNSL. In various case series, the addition of CHOP to HD-MTX resulted in increased toxicity with no improvement in survival. There is a rapid response with CHOP regimen, but also early relapse and progressive disease. Anthracyclines act mainly in the area where blood brain barrier is disrupted and hence the rapid response. With the attainment of response, the BBB is normalized and hence anthracyclines no longer act on the microscopic disease and hence the response is short lived.  In the CSF, rituximab reaches 0.1% of the serum concentration.  Therefore, its role is not clear in the management of PCNSL. Schultz et al. in 1996 reported 52 patients of PCNSL treated with CHOP with RT having median survival of 16.1 months. 
|Table 4: Comparison of various studies using DeAngelis protocol and the current study with outcome|
Click here to view
|Table 5: Patient characteristics in the present study (where DeAngelis protocol was used)|
Click here to view
| Conclusion|| |
To conclude, the treatment of PCNSL with a HD-MTX combined with cranial irradiation is an effective therapeutic approach to PCNSL. Despite treatment, the outcome is dismal. It needs the development of new protocols involving high-dose or intraventricular polychemotherapy, rituximab, consolidating radiotherapy, high-dose chemotherapy followed by stem cell rescue. It is of utmost importance to search for new effective and tolerable treatment strategies in case of recurrence. Therapeutic options for PCNSLs in immunocompromised patients should be more thoroughly investigated. Integration of fluoro-deoxyglucose positron emission tomography into prospective trials is warranted to investigate prognostic and therapeutic implications. The strength of the current study includes the large number of patients from a single institution and limitations include the inadequate follow-up. There is limited data on this entity from the sub-continent and hence adds to the current literature. However, further studies are required incorporating newer regimens like the methotrexate, temozolamide and rituximab (MTR regimen) and also on the role of autologous stem cell transplantation.
| Acknowledgment|| |
I thank all the staff and students of Department of Medical Oncology.
| References|| |
Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, et al.
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407-14.
Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, et al
. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010;67:182-9.
Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: A series of 33 cases. Eur J Surg Oncol 2005;31:100-5.
DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8.
Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al.
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-91.
Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol 2010;67:291-7.
Flanagan EP, O′Neill BP, Porter AB, Lanzino G, Haberman TM, Keegan BM. Primary intramedullary spinal cord lymphoma. Neurology 2011;77:784-91.
Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin′s lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383-97.
Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, et al.
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011;25:1797-807.
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al.
Gene expression and angiotropism in primary CNS lymphoma. Blood 2006;107:3716-23.
El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-74.
Ferreri AJ, Dell′Oro S, Capello D, Ponzoni M, Iuzzolino P, Rossi D, et al.
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 2004;126:657-64.
Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, Schmidt-Wolf IG, et al.
The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer 2004;90:1969-71.
Takeuchi H, Matsuda K, Kitai R, Sato K, Kubota T. Angiogenesis in primary central nervous system lymphoma (PCNSL). J Neurooncol 2007;84:141-5.
Coté TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996;88:675-9.
Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al.
Primary intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg 2000;92:261-6.
Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, et al.
Intraocular lymphoma 2000-2005: Results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 2006;244:663-9.
Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al.
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43.
Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al.
A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-20.
Küker W, Nägele T, Korfel A, Heckl S, Thiel E, Bamberg M, et al.
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005;72:169-77.
Kawai N, Okubo S, Miyake K, Maeda Y, Yamamoto Y, Nishiyama Y, et al.
Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med 2010;24:335-43.
Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al.
Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711-5.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al.
Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72.
Yi JQ, Lin TY, He YJ, Huang HQ, Xia ZJ, Xia YF, et al.
Primary central nervous system lymphoma - a report of 32 cases with literature review. Ai Zheng 2006;25:476-80.
Agarwal PA, Menon S, Smruti BK, Singhal BS. Primary central nervous system lymphoma: A profile of 26 cases from Western India. Neurol India 2009;57:756-63.
Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al.
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-5.
Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al
. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31:3061-8.
Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, et al.
A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: Cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000;89:1359-70.
Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al.
Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood 2003;101:466-8.
Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al.
Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group Protocol 88-06. J Clin Oncol 1996;14:556-64.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]